Eisai Takes Biggest Cuts From Japan’s Drug Price Cuts
This article was originally published in PharmAsia News
Executive Summary
Eisai stands to be Japan’s biggest loser among local drug makers when the new cap on drug prices takes effect in April, according to a calculation of the effect on the nation’s top four companies.